Journal
INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS
Volume 28, Issue 1, Pages -Publisher
SPRINGER
DOI: 10.1007/s10989-021-10311-y
Keywords
Mycoplasma; Antimicrobial activity; Medicinal plants; Antimicrobial peptide; Intravenous immunoglobulin; Phage display
Categories
Ask authors/readers for more resources
Mycoplasma is a bacterium without a cell wall, making it naturally resistant to antibiotics. Some species are pathogenic to humans, and antibiotic-resistant strains are increasing worldwide.
Mycoplasma is a bacterium that lacks a cell wall around its cell membrane, that makes it naturally resistant to antibiotics such as beta-lactams, which target cell wall synthesis. These bacteria can be parasitic or saprotrophic. Several species of these bacteria are pathogenic in humans, including M. pneumoniae and M. genitalium. Mycoplasma pneumoniae infection occurs worldwide and is more prevalent in colder months. It affects mainly children aged 5 to 9 years. It is spread by close personal contact and has a long incubation period. Ureaplasma urealyticum is spread primarily through sexual contact. Women may be asymptomatic reservoirs. Mycoplasma species are usually sensitive to tetracyclines, macrolides, and the newer quinolones. Tetracycline or erythromycin is recommended for treatment of M. pneumoniae, although effective treatment of the symptoms usually is not accompanied by eradication of the organism from the infected host. The antibiotic-resistant strains of Mycoplasma spp. are increasing worldwide, therefore, the aim of this review was to assess new methods and approaches for treatment of infections caused by Mycoplasma species.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available